3y
When the Covid Pandemic struck, Novacyt was uniquely positioned to provide the tests to detect the virus in a very speedy manner, and to develop these as the various strains evolved. The company grew in terms of revenue, customer numbers and of course staff numbers to support the battle against Covid. The business did recognise that Covid testing demands would reduce and work was done to build up other business areas. Novacyt is interested primarily in technologies applied to human infectious disease diagnostics and screening, and adjacent markets. These include: Respiratory, Gastrointestinal, Transplant, Insect-borne diseases. We are also considering additional unmet needs in infectious diseases including sexually transmitted infections (STI), urinary tract infections (UTI), hospital acquired infections, meningitis/encephalitis and sepsis. There are some business areas which we have now withdrawn from, as they did not sit in our focus, which is very much on infectious diseases. With very deep regret a number of posts were made redundant and after a period of consultation, sadly a number of people left the organisation. However, they left knowing the impact they made to the battle against Covid, the big impact that they and the company had on fighting the pandemic, and left with skills and experience gained during this unique period of world history.
